All news

Treatment for Neurofibromatosis type 2 (NF2)

Dec 23, 2024

Bevacizumab for Respiratory Papillomatosis

Dec 23, 2024

Orphan Drug Designation Kawasaki Disease

Dec 20, 2024

ODDIFACT develops and licenses Orphan Drug Designations (ODDs). An ODD is not an approved drug, treatment, or therapy, and does not imply safety, efficacy, or regulatory approval.
ODDIFACT provides neither medical advice nor treatment recommendations. Only qualified healthcare professionals can determine what therapies are appropriate for individual patients.
We disclaim all liability for any use, misuse, or interpretation of ODDs developed or licensed by our company.

Company Information:

Oddifact SAS: Company with registered capital of 100 000 euros.

Registration in the trade and companies register under number 985 380 138 R.C.S. Paris, France.

Activity (NAF/APE): Computer programming (62.01Z)

The Publication Director is the president of Oddifact

The development and integration of the website are provided by Oddifact

The website is hosted by Wix